Imara
-
Cancer drug biotech Enliven shifts to reverse to move forward as a public company
Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.
-
Imara’s two trial flops in blood disorders dim drug’s prospects in heart failure
The lead drug candidate of Imara failed two separate mid-stage clinical trials evaluating it in rare, inherited hemoglobin disorders. Imara had been planning to advance the small molecule to yet another Phase 2 study in heart failure, but in light of the twin trial failures, the biotech is now weighing “strategic options.”
-
Streamline the Process for Consent Collection and Management
Join us on April 16th and hear executives from DocuSign and Velatura discuss how their partnership modernizes and facilitates the efficient and secure completion of the patient consent form.
-
Imara closes $63M Series B funding round for blood disorder drug development
The company is developing a drug that targets the same pathway as the chemotherapy agent hydroxyurea, but is designed for a better safety profile.